全文获取类型
收费全文 | 7593篇 |
免费 | 528篇 |
国内免费 | 15篇 |
专业分类
耳鼻咽喉 | 100篇 |
儿科学 | 252篇 |
妇产科学 | 164篇 |
基础医学 | 910篇 |
口腔科学 | 75篇 |
临床医学 | 1010篇 |
内科学 | 1350篇 |
皮肤病学 | 112篇 |
神经病学 | 724篇 |
特种医学 | 183篇 |
外科学 | 812篇 |
综合类 | 75篇 |
一般理论 | 3篇 |
预防医学 | 1096篇 |
眼科学 | 217篇 |
药学 | 483篇 |
中国医学 | 5篇 |
肿瘤学 | 565篇 |
出版年
2024年 | 8篇 |
2023年 | 71篇 |
2022年 | 137篇 |
2021年 | 268篇 |
2020年 | 170篇 |
2019年 | 202篇 |
2018年 | 262篇 |
2017年 | 205篇 |
2016年 | 197篇 |
2015年 | 236篇 |
2014年 | 314篇 |
2013年 | 441篇 |
2012年 | 622篇 |
2011年 | 655篇 |
2010年 | 365篇 |
2009年 | 322篇 |
2008年 | 500篇 |
2007年 | 481篇 |
2006年 | 442篇 |
2005年 | 479篇 |
2004年 | 423篇 |
2003年 | 376篇 |
2002年 | 326篇 |
2001年 | 53篇 |
2000年 | 40篇 |
1999年 | 44篇 |
1998年 | 44篇 |
1997年 | 53篇 |
1996年 | 28篇 |
1995年 | 23篇 |
1994年 | 16篇 |
1993年 | 8篇 |
1992年 | 18篇 |
1991年 | 20篇 |
1990年 | 18篇 |
1989年 | 11篇 |
1988年 | 17篇 |
1987年 | 8篇 |
1986年 | 24篇 |
1985年 | 18篇 |
1984年 | 16篇 |
1983年 | 24篇 |
1982年 | 16篇 |
1981年 | 14篇 |
1980年 | 10篇 |
1979年 | 15篇 |
1978年 | 10篇 |
1976年 | 10篇 |
1975年 | 9篇 |
1970年 | 11篇 |
排序方式: 共有8136条查询结果,搜索用时 15 毫秒
81.
82.
Christof Kaltenmeier Dana Jorgensen Stalin Dharmayan Subhashini Ayloo Vikrant Rachakonda David A. Geller Samer Tohme Michele Molinari 《HPB : the official journal of the International Hepato Pancreato Biliary Association》2021,23(6):927-936
BackgroundWe assessed if the risk of post-liver transplant mortality within 24 h could be stratified at the time of listing using the liver transplant risk score (LTRS). Secondary aims were to assess if the LTRS could stratify the risk of 30-day, 1-year mortality, and survival beyond the first year.MethodsMELD, BMI, age, diabetes, and the need for dialysis were the five variables used to calculate the LTRS during patients' evaluation for liver transplantation. Mortality rates at 24 h, 30 days, and 1-year were compared among groups of patients with different LTRS. Patients with ABO-incompatibility, redo, multivisceral, partial graft and malignancies except for hepatocellular carcinoma were excluded. Data of 48,616 adult liver transplant recipients were extracted from the Scientific Registry of Transplant Recipients between 2002 and 2017.Results24-h mortality was 0.9%, 1.0%, 1.1%, 1.7%, 2.3%, 2.0% and 3.5% for patients with LTRS of 0,1,2,3,4, 5 and ≥ 6, respectively (P < 0.001). 30-day mortality was 3.5%, 4.2%, 4.9%, 6.2%, 7.6%, 7.2% and 10.1% respectively (P < 0.001). 1-year mortality was 8.6%, 10.8%, 12.9%, 13.9%, 18.5%, 20.3% and 28.6% respectively (P < 0.001). 10-year survival was 61%, 56%, 57%, 54%, 47%, and 31% for patients with 0, 1, 2, 3, 4, 5 and ≥ 6 points respectively (P < 0.001).ConclusionPerioperative mortality and long-term survival of patients undergoing LT can be accurately estimated at the time of listing by the LTRS. 相似文献
83.
Maria Adriana Neag rei Otto Mitre Adrian Catinean Anca Dana Buzoianu 《World journal of gastroenterology : WJG》2021,27(43):7446-7461
Viral B and C hepatitis are a major current health issue, both diseases having a chronic damaging effect on the liver and its functions. Chronic liver disease can lead to even more severe and life-threatening conditions, such as liver cirrhosis and hepatocellular carcinoma. Recent years have uncovered an important interplay between the liver and the gut microbiome: the gut-liver axis. Hepatitis B and C infections often cause alterations in the gut microbiota by lowering the levels of ‘protective’ gut microorganisms and, by doing so, hinder the microbiota ability to boost the immune response. Treatments aimed at restoring the gut microbiota balance may provide a valuable addition to current practice therapies and may help limit the chronic changes observed in the liver of hepatitis B and C patients. This review aims to summarize the current knowledge on the anato-functional axis between the gut and liver and to highlight the influence that hepatitis B and C viruses have on the microbiota balance, as well as the influence of treatments aimed at restoring the gut microbiota on infected livers and disease progression. 相似文献
84.
85.
86.
87.
88.
89.
Mutaz Dana 《Hemoglobin》2018,42(2):138-140
The major hemoglobin (Hb) during fetal life is fetal Hb (Hb F). It is mostly replaced by adult Hbs before birth and during the first year of life. In adults, where Hb F comprises <2.0% of the total Hb, it is not homogenously distributed among the red blood cells (RBCs) but is concentrated in a few RBCs, termed F-cells. Interestingly, for reasons that are unclear, Hb F increases in the maternal circulation during pregnancy. This increased Hb F could have two potential origins that are not mutually exclusive: A) maternal origin, due to inducing environment of Hb F in the maternal erythroid precursors; B) fetal origin, due to fetal cells crossing the placenta and entering the maternal circulation. The question we present herein is whether the observed increased Hb F in the maternal circulation during pregnancy is, at least partially, derived from the fetal origin. Peripheral blood was obtained from normal neonates (1–3 days old), adult men and pregnant and non pregnant women. The RBCs were stained for Hb F and carbonic anhydrase (CA) using a fetal cell count kit and analyzed by flow cytometry. Fetal and adult F-cells were distinguished by their expression of Hb F and CA. Fetal F-cells were Hb F++/CA?, while adult F-cells were Hb F+/CA+. Comparing pregnant and non pregnant women samples (n?=?10), we found six samples of pregnant women with 0.2–1.7% fetal cells, but none in the non pregnant group. These results support the possibility that at least part of the increase in Hb F during pregnancy is due to fetal cells entering the maternal circulation. 相似文献
90.